Share Price and Basic Stock Data
Last Updated: November 28, 2025, 10:50 am
| PEG Ratio | 0.59 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Deepak Chemtex Ltd operates in the Dyes & Pigments sector, with its stock currently priced at ₹108 and a market capitalization of ₹117 Cr. The company’s revenue has shown variability over recent years, with sales reported at ₹29 Cr in March 2021, rising to ₹54 Cr in March 2022, and subsequently declining to ₹46 Cr in March 2023. However, sales recovered to ₹50 Cr in March 2024 and are projected to reach ₹68 Cr by March 2025. This indicates a positive growth trajectory, particularly in the most recent fiscal year, which may reflect improved demand for its products. The operating profit margin (OPM) has fluctuated, recording 14% in FY 2021, dipping to 12% in FY 2022, then rebounding to 17% in FY 2023 and maintaining at 17% in FY 2024, with an increase to 19% anticipated for FY 2025. The company’s performance reflects its ability to navigate market challenges while capitalizing on opportunities within the industry.
Profitability and Efficiency Metrics
Deepak Chemtex Ltd’s profitability metrics demonstrate a robust financial standing, with a net profit of ₹10 Cr reported for the fiscal year ending March 2025, up from ₹7 Cr in March 2024 and ₹6 Cr in March 2023. The earnings per share (EPS) also reflect this upward momentum, standing at ₹11.51 for March 2025, which is a significant increase compared to ₹6.71 in March 2024. The company’s return on equity (ROE) is strong at 20.9%, indicating effective utilization of shareholder funds, while the return on capital employed (ROCE) stands at 28.1%, suggesting efficient capital management. The interest coverage ratio (ICR) is exceptionally high at 180.40x, indicating that the company has ample earnings to cover its interest obligations, reflecting low financial risk. The cash conversion cycle (CCC) was reported at 90 days, suggesting that the company efficiently manages its receivables and inventory, which is crucial in the competitive dyes and pigments market.
Balance Sheet Strength and Financial Ratios
Deepak Chemtex Ltd’s balance sheet exhibits strength, particularly with a low long-term debt to equity ratio of 0.01, indicating minimal reliance on debt financing. This is complemented by a current ratio of 3.29, significantly above the typical industry benchmark of 1.5, suggesting that the company is well-positioned to meet its short-term liabilities. The price-to-book value (P/BV) ratio stands at 2.16x, which is indicative of a reasonable valuation compared to its book value per share of ₹50.75. The company has reported no borrowings, aligning with its conservative financial strategy that prioritizes financial stability. Additionally, the net profit margin improved to 15.74% in March 2025 from 12.10% in March 2024, highlighting an increase in profitability relative to sales, which further enhances its financial health and operational efficiency.
Shareholding Pattern and Investor Confidence
Deepak Chemtex Ltd’s shareholding pattern reveals a strong promoter holding of 73.05%, indicating significant insider confidence in the company’s future. Institutional ownership is negligible, with foreign institutional investors (FIIs) holding 0.00% and domestic institutional investors (DIIs) at a mere 1.16% as of March 2024. This lack of institutional investment could imply a potential risk regarding market perception and liquidity. The public shareholding has fluctuated slightly, standing at 26.94% as of March 2025, which may reflect a stable investor base. The number of shareholders decreased from 1,017 in March 2024 to 907 in March 2025, suggesting a consolidation of ownership. The high promoter stake, while generally positive, may also raise concerns about the lack of external oversight and diversification in ownership, which can impact governance and decision-making.
Outlook, Risks, and Final Insight
Looking ahead, Deepak Chemtex Ltd appears well-positioned for growth, particularly with the anticipated increase in sales to ₹68 Cr by March 2025 and a steady improvement in profitability metrics. However, risks remain, including the company’s heavy reliance on domestic markets with no foreign institutional investment, which may expose it to local economic fluctuations. The rising cash conversion cycle to 90 days poses a concern regarding liquidity management, particularly if market conditions worsen. Additionally, the lack of reserves may limit the company’s ability to fund expansion or navigate downturns effectively. In summary, while Deepak Chemtex Ltd demonstrates solid financial health and growth potential, stakeholders should closely monitor its operational efficiency and market dynamics to mitigate inherent risks. The company’s strong fundamentals provide a foundation for future success, contingent on effective management of its resources and market positioning.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Deepak Chemtex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Deepak Chemtex Ltd | 113 Cr. | 104 | 175/93.5 | 13.7 | 52.4 | 0.00 % | 28.1 % | 20.9 % | 10.0 |
| Prolife Industries Ltd | 33.4 Cr. | 81.7 | 361/78.3 | 13.9 | 115 | 0.37 % | 14.4 % | 10.8 % | 10.0 |
| Industry Average | 113.00 Cr | 92.85 | 13.80 | 83.70 | 0.19% | 21.25% | 15.85% | 10.00 |
Quarterly Result
| Metric | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|
| Sales | 29 | 33 | 35 |
| Expenses | 24 | 26 | 29 |
| Operating Profit | 4 | 7 | 6 |
| OPM % | 15% | 21% | 17% |
| Other Income | 1 | 1 | 2 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 1 | 1 |
| Profit before tax | 5 | 7 | 7 |
| Tax % | 26% | 24% | 30% |
| Net Profit | 3 | 5 | 5 |
| EPS in Rs | 3.20 | 4.83 | 4.44 |
Last Updated: July 16, 2025, 10:13 am
Below is a detailed analysis of the quarterly data for Deepak Chemtex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Sep 2024) to 35.00 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Mar 2025, the value is 29.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Sep 2024) to 29.00 Cr., marking an increase of 3.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Sep 2024) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Mar 2025, the value is 17.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Sep 2024) to 17.00%, marking a decrease of 4.00%.
- For Other Income, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Sep 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 7.00 Cr..
- For Tax %, as of Mar 2025, the value is 30.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Sep 2024) to 30.00%, marking an increase of 6.00%.
- For Net Profit, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 5.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.44. The value appears to be declining and may need further review. It has decreased from 4.83 (Sep 2024) to 4.44, marking a decrease of 0.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:55 pm
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Sales | 29 | 54 | 46 | 50 | 68 |
| Expenses | 25 | 48 | 39 | 42 | 55 |
| Operating Profit | 4 | 6 | 8 | 9 | 13 |
| OPM % | 14% | 12% | 17% | 17% | 19% |
| Other Income | 0 | 0 | 1 | 1 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 4 | 6 | 8 | 9 | 14 |
| Tax % | 28% | 26% | 25% | 25% | 27% |
| Net Profit | 3 | 4 | 6 | 7 | 10 |
| EPS in Rs | 6.10 | 9.27 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.33% | 50.00% | 16.67% | 42.86% |
| Change in YoY Net Profit Growth (%) | 0.00% | 16.67% | -33.33% | 26.19% |
Deepak Chemtex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
Last Updated: September 5, 2025, 3:11 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 65 | 57 | 88 | 110 | 90 |
| Inventory Days | 44 | 21 | 54 | 56 | 51 |
| Days Payable | 65 | 37 | 54 | 46 | 51 |
| Cash Conversion Cycle | 43 | 41 | 88 | 120 | 90 |
| Working Capital Days | 37 | 43 | 81 | 96 | 78 |
| ROCE % | 61% | 58% | 29% | 28% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 100.00 | 100.00 |
| Basic EPS (Rs.) | 11.51 | 6.71 | 7.90 | 5.30 |
| Diluted EPS (Rs.) | 11.51 | 6.71 | 7.90 | 5.30 |
| Cash EPS (Rs.) | 13.49 | 6.28 | 1396.53 | 956.65 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 50.75 | 38.62 | 3147.07 | 1882.56 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 50.75 | 38.62 | 3147.07 | 1882.56 |
| Revenue From Operations / Share (Rs.) | 73.13 | 45.43 | 9359.29 | 10843.42 |
| PBDIT / Share (Rs.) | 17.47 | 8.37 | 1835.07 | 1257.31 |
| PBIT / Share (Rs.) | 15.49 | 7.59 | 1703.10 | 1148.55 |
| PBT / Share (Rs.) | 15.39 | 7.56 | 1689.43 | 1129.59 |
| Net Profit / Share (Rs.) | 11.51 | 5.50 | 1264.56 | 847.89 |
| NP After MI And SOA / Share (Rs.) | 11.38 | 5.50 | 1264.56 | 847.89 |
| PBDIT Margin (%) | 23.88 | 18.43 | 19.60 | 11.59 |
| PBIT Margin (%) | 21.18 | 16.70 | 18.19 | 10.59 |
| PBT Margin (%) | 21.05 | 16.63 | 18.05 | 10.41 |
| Net Profit Margin (%) | 15.74 | 12.10 | 13.51 | 7.81 |
| NP After MI And SOA Margin (%) | 15.55 | 12.10 | 13.51 | 7.81 |
| Return on Networth / Equity (%) | 22.41 | 14.23 | 40.20 | 45.08 |
| Return on Capital Employeed (%) | 29.89 | 19.48 | 53.05 | 58.05 |
| Return On Assets (%) | 17.54 | 11.72 | 26.48 | 24.66 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.02 |
| Total Debt / Equity (X) | 0.01 | 0.03 | 0.08 | 0.21 |
| Asset Turnover Ratio (%) | 1.31 | 1.32 | 2.28 | 0.00 |
| Current Ratio (X) | 3.29 | 4.98 | 2.44 | 1.92 |
| Quick Ratio (X) | 2.50 | 4.22 | 1.89 | 1.62 |
| Inventory Turnover Ratio (X) | 8.94 | 5.40 | 8.32 | 0.00 |
| Interest Coverage Ratio (X) | 180.40 | 257.73 | 134.27 | 66.32 |
| Interest Coverage Ratio (Post Tax) (X) | 119.91 | 170.20 | 93.52 | 45.73 |
| Enterprise Value (Cr.) | 114.22 | 53.62 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.44 | 1.09 | 0.00 | 0.00 |
| EV / EBITDA (X) | 6.02 | 5.89 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.50 | 1.45 | 0.00 | 0.00 |
| Price / BV (X) | 2.16 | 1.71 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.50 | 1.45 | 0.00 | 0.00 |
| EarningsYield | 0.10 | 0.08 | 0.00 | 0.00 |
After reviewing the key financial ratios for Deepak Chemtex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has increased from 6.71 (Mar 24) to 11.51, marking an increase of 4.80.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has increased from 6.71 (Mar 24) to 11.51, marking an increase of 4.80.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.49. This value is within the healthy range. It has increased from 6.28 (Mar 24) to 13.49, marking an increase of 7.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.75. It has increased from 38.62 (Mar 24) to 50.75, marking an increase of 12.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.75. It has increased from 38.62 (Mar 24) to 50.75, marking an increase of 12.13.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 73.13. It has increased from 45.43 (Mar 24) to 73.13, marking an increase of 27.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.47. This value is within the healthy range. It has increased from 8.37 (Mar 24) to 17.47, marking an increase of 9.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 15.49. This value is within the healthy range. It has increased from 7.59 (Mar 24) to 15.49, marking an increase of 7.90.
- For PBT / Share (Rs.), as of Mar 25, the value is 15.39. This value is within the healthy range. It has increased from 7.56 (Mar 24) to 15.39, marking an increase of 7.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has increased from 5.50 (Mar 24) to 11.51, marking an increase of 6.01.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.38. This value is within the healthy range. It has increased from 5.50 (Mar 24) to 11.38, marking an increase of 5.88.
- For PBDIT Margin (%), as of Mar 25, the value is 23.88. This value is within the healthy range. It has increased from 18.43 (Mar 24) to 23.88, marking an increase of 5.45.
- For PBIT Margin (%), as of Mar 25, the value is 21.18. This value exceeds the healthy maximum of 20. It has increased from 16.70 (Mar 24) to 21.18, marking an increase of 4.48.
- For PBT Margin (%), as of Mar 25, the value is 21.05. This value is within the healthy range. It has increased from 16.63 (Mar 24) to 21.05, marking an increase of 4.42.
- For Net Profit Margin (%), as of Mar 25, the value is 15.74. This value exceeds the healthy maximum of 10. It has increased from 12.10 (Mar 24) to 15.74, marking an increase of 3.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.55. This value is within the healthy range. It has increased from 12.10 (Mar 24) to 15.55, marking an increase of 3.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 22.41. This value is within the healthy range. It has increased from 14.23 (Mar 24) to 22.41, marking an increase of 8.18.
- For Return on Capital Employeed (%), as of Mar 25, the value is 29.89. This value is within the healthy range. It has increased from 19.48 (Mar 24) to 29.89, marking an increase of 10.41.
- For Return On Assets (%), as of Mar 25, the value is 17.54. This value is within the healthy range. It has increased from 11.72 (Mar 24) to 17.54, marking an increase of 5.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.31. It has decreased from 1.32 (Mar 24) to 1.31, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.29. This value exceeds the healthy maximum of 3. It has decreased from 4.98 (Mar 24) to 3.29, marking a decrease of 1.69.
- For Quick Ratio (X), as of Mar 25, the value is 2.50. This value exceeds the healthy maximum of 2. It has decreased from 4.22 (Mar 24) to 2.50, marking a decrease of 1.72.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.94. This value exceeds the healthy maximum of 8. It has increased from 5.40 (Mar 24) to 8.94, marking an increase of 3.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 180.40. This value is within the healthy range. It has decreased from 257.73 (Mar 24) to 180.40, marking a decrease of 77.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 119.91. This value is within the healthy range. It has decreased from 170.20 (Mar 24) to 119.91, marking a decrease of 50.29.
- For Enterprise Value (Cr.), as of Mar 25, the value is 114.22. It has increased from 53.62 (Mar 24) to 114.22, marking an increase of 60.60.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.44. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.44, marking an increase of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 6.02. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 6.02, marking an increase of 0.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.50. This value is within the healthy range. It has increased from 1.45 (Mar 24) to 1.50, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 2.16. This value is within the healthy range. It has increased from 1.71 (Mar 24) to 2.16, marking an increase of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.50. This value is within the healthy range. It has increased from 1.45 (Mar 24) to 1.50, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.08 (Mar 24) to 0.10, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Deepak Chemtex Ltd:
- Net Profit Margin: 15.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 29.89% (Industry Average ROCE: 21.25%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 22.41% (Industry Average ROE: 15.85%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 119.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.5
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 13.7 (Industry average Stock P/E: 13.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Dyes & Pigments | Aawashi, 28/1A, A/P Adgul Aawashi, Ratnagiri Maharashtra 415722 | saurabh@deepakchemtex.in https://www.deepakchemtex.in/ |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Saurbah Deepak Arora | Chairman & Managing Director |
| Mrs. Trishla Baid | WholeTime Director & CFO |
| Mr. Rajesh Kalikaprasad Tiwari | Executive Director |
| Mr. Narendra Kumar Baid | Non Executive Director |
| Mr. Gautam Lath | Independent Director |
| Mrs. Pinki Kedia | Independent Director |